These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1381298)

  • 21. Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality.
    Grimm EA
    Biochim Biophys Acta; 1986 Dec; 865(3):267-79. PubMed ID: 3539198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.
    Phillips JH; Gemlo BT; Myers WW; Rayner AA; Lanier LL
    J Clin Oncol; 1987 Dec; 5(12):1933-41. PubMed ID: 3500280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.
    Phillips JH; Lanier LL
    J Exp Med; 1986 Sep; 164(3):814-25. PubMed ID: 3489062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peripheral blood natural killer cell activity in human breast cancer patients and its modulation by T-cell growth factor and autologous plasma.
    Brenner BG; Benarrosh S; Margolese RG
    Cancer; 1986 Aug; 58(4):895-902. PubMed ID: 3487379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of defective natural killer cell activity in patients with AIDS is associated with defective distribution of tubulin.
    Sirianni MC; Soddu S; Malorni W; Arancia G; Aiuti F
    J Immunol; 1988 Apr; 140(8):2565-8. PubMed ID: 3356900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural killer cell infection and inactivation in vitro by the human immunodeficiency virus.
    Robinson WE; Mitchell WM; Chambers WH; Schuffman SS; Montefiori DC; Oeltmann TN
    Hum Pathol; 1988 May; 19(5):535-40. PubMed ID: 3286479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of functional surface structures on human natural killer cells.
    Ritz J; Schmidt RE; Michon J; Hercend T; Schlossman SF
    Adv Immunol; 1988; 42():181-211. PubMed ID: 3284289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The difference in surface phenotypes between cytotoxic lymphocytes induced in vivo by systemic administration of human recombinant interleukin-2 and lymphokine activated killer cells induced in vitro.
    Ozaki A; Nakano H; Minato K; Nakagawa K; Sasaki Y; Saijo N
    Eur J Cancer Clin Oncol; 1988 Jun; 24(6):1055-60. PubMed ID: 3261691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective depletion of low-density CD8+, CD16+ lymphocytes during HIV infection.
    Vuillier F; Bianco NE; Montagnier L; Dighiero G
    AIDS Res Hum Retroviruses; 1988 Apr; 4(2):121-9. PubMed ID: 3259141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
    McMannis JD; Fisher RI; Creekmore SP; Braun DP; Harris JE; Ellis TM
    J Immunol; 1988 Feb; 140(4):1335-40. PubMed ID: 3257776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphokine-activated killer cells. Analysis of progenitors and effectors.
    Ortaldo JR; Mason A; Overton R
    J Exp Med; 1986 Oct; 164(4):1193-205. PubMed ID: 3093626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human natural lymphocyte effector cells: definition, analysis of activity, and clinical effectiveness.
    Ortaldo JR; Longo DL
    J Natl Cancer Inst; 1988 Sep; 80(13):999-1010. PubMed ID: 3045334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of alpha interferon production with natural killer cell lysis of U937 cells infected with human immunodeficiency virus.
    Rappocciolo G; Toso JF; Torpey DJ; Gupta P; Rinaldo CR
    J Clin Microbiol; 1989 Jan; 27(1):41-8. PubMed ID: 2913035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells.
    Kedar E; Rezai AR; Giorgi JV; Gale RP; Champlin RE; Mitsuyasu RT; Fahey JL
    Nat Immun Cell Growth Regul; 1988; 7(1):13-30. PubMed ID: 2896298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human lymphokine-activated killer cells: further isolation and characterization of the precursor and effector cell.
    Skibber JM; Lotze MT; Muul LM; Uppenkamp IK; Ross W; Rosenberg SA
    Nat Immun Cell Growth Regul; 1987; 6(6):291-305. PubMed ID: 2896297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals.
    Weinhold KJ; Lyerly HK; Matthews TJ; Tyler DS; Ahearne PM; Stine KC; Langlois AJ; Durack DT; Bolognesi DP
    Lancet; 1988 Apr; 1(8591):902-5. PubMed ID: 2895830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.
    Gambacorti-Passerini C; Rivoltini L; Radrizzani M; Belli F; Sciorelli G; Ravagnani F; Galazka AR; Cascinelli N; Parmiani G
    Cancer Res; 1989 Sep; 49(18):5230-4. PubMed ID: 2788498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biology of natural killer cells.
    Trinchieri G
    Adv Immunol; 1989; 47():187-376. PubMed ID: 2683611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases.
    Brenner BG; Dascal A; Margolese RG; Wainberg MA
    J Leukoc Biol; 1989 Jul; 46(1):75-83. PubMed ID: 2659714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection.
    Ljunggren K; Karlson A; Fenyö EM; Jondal M
    Clin Exp Immunol; 1989 Feb; 75(2):184-9. PubMed ID: 2649286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.